Compounds > phenylalanine

phenylalanine and Granulocytic Leukemia, Chronic

phenylalanine has been researched along with Granulocytic Leukemia, Chronic in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's4 (36.36)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allende-Alarcón, LI; Martínez-García, M; Martínez-Klimova, E; Mendoza-Cardozo, S; Organista-Mateos, U; Pedro-Hernández, LD; Ramírez-Ápan, T1
Divoka, M; Divoky, V; Faber, E; Indrak, K; Jarosova, M; Mojzikova, R; Plachy, R; Rozmanova, S; Stastny, M1
Bay, JO; Berger, MG; Chaleteix, C; Fleury, J; Gouas, L; Goumy, C; Ledoux-Pilon, A; Richard-Pebrel, C; Tchirkov, A; Tournilhac, O; Vago, P; Véronèse, L1
Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O1
Brasher, BB; Gorre, ME; Nicoll, J; Roumiantsev, S; Sawyers, CL; Shah, NP; Van Etten, RA1
Mahon, FX1
Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N1
Rosenfeld, CS1
Bassing, CH; Batzer, A; Cripe, LD; Dai, Z; Der, CJ; Li, N; Pendergast, AM; Quilliam, LA; Rabun, KM; Schlessinger, J1
Pangalis, GA; Tsavaris, NB1
Million, RP; Van Etten, RA1

Other Studies

11 other study(ies) available for phenylalanine and Granulocytic Leukemia, Chronic

ArticleYear
In vitro activity of resorcinarene-chlorambucil conjugates for therapy in human chronic myelogenous leukemia cells.
    Drug development and industrial pharmacy, 2019, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Calixarenes; Chlorambucil; Dendrimers; Drug Carriers; Drug Screening Assays, Antitumor; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenylalanine

2019
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Amino Acid Substitution; Antineoplastic Agents; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylalanine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles; Treatment Outcome

2010
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
    Leukemia research, 2010, Volume: 34, Issue:4

    Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Phenylalanine; Piperazines; Pyrimidines; Thrombocytosis; Valine

2010
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
    Leukemia research, 2012, Volume: 36, Issue:1

    Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome

2012
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Proceedings of the National Academy of Sciences of the United States of America, 2002, Aug-06, Volume: 99, Issue:16

    Topics: Antineoplastic Agents; Benzamides; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenylalanine; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Tyrosine

2002
JAK the trigger.
    Oncogene, 2005, Nov-03, Volume: 24, Issue:48

    Topics: Amino Acid Substitution; Autoantigens; Cell Cycle Proteins; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Enzyme Activation; Humans; Janus Kinase 2; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Phenylalanine; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Translocation, Genetic

2005
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Adult; Antineoplastic Agents; Blast Crisis; Clinical Trials, Phase II as Topic; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure

2006
Antileukemic activity of phenylalanine methyl ester (PME): a lysosomotropic peptide methyl ester.
    Stem cells (Dayton, Ohio), 1994, Volume: 12, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Child; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monocytes; Phenylalanine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temperature; Tumor Cells, Cultured

1994
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
    Cell, 1993, Oct-08, Volume: 75, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Animals; Binding Sites; Cell Line; Cell Transformation, Neoplastic; Exons; Fusion Proteins, bcr-abl; Genes, abl; GRB2 Adaptor Protein; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Moths; Mutagenesis, Site-Directed; Phenylalanine; Point Mutation; Promoter Regions, Genetic; Protein Binding; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Proto-Oncogenes; Recombinant Fusion Proteins; Transcription, Genetic; Tumor Cells, Cultured

1993
Neutrophil 5-nucleotidase reaction in chronic myelogenous leukemia, myelofibrosis with myeloid metaplasia, and polycythemia vera.
    Annals of hematology, 1998, Volume: 76, Issue:1

    Topics: 5'-Nucleotidase; Adenosine Diphosphate; Adjuvants, Immunologic; Alkaline Phosphatase; Enzyme Inhibitors; Homoarginine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Levamisole; Neutrophils; Phenylalanine; Polycythemia Vera; Primary Myelofibrosis

1998
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Blood, 2000, Jul-15, Volume: 96, Issue:2

    Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Animals; Binding Sites; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; GRB2 Adaptor Protein; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Neoplasm Transplantation; Phenylalanine; Proteins; Structure-Activity Relationship; Transfection; Tyrosine

2000